Close Menu

NEW YORK (GenomeWeb) – Owlstone Medical, a UK-based firm developing a "breathalyzer" technology for non-invasive diagnosis of cancer, infectious disease, and inflammatory disease, is gearing up to market its first test to screen patients for lung and colon cancer.

To that end, in June Owlstone Medical announced closing approximately $7M in investment funding, led by the UK's Medtekwiz Advisory, to help commercialize the assay.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 


This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.